CELLINK, a global leader in 3D bioprinting technologies, is excited to announce a strategic distribution agreement with Paralab, marking a significant expansion of its presence in Portugal and Spain. This collaboration brings CELLINK’s state-of-the-art bioprinting solutions to a broader audience in Southern Europe, reinforcing the company’s commitment to advancing regenerative medicine while respecting regional nuances.
Paralab has more than 30 years of experience in distributing scientific equipment for industrial and laboratory applications. This partnership, driven by a mutual commitment to empowering researchers and advancing scientific discovery, holds the potential to be a transformative development for the local bioprinting community.
By leveraging Paralab’s strong regional presence and reputation, along with CELLINK’s cutting-edge bioprinting solutions, Paralab along with its Bio division, is strategically positioned to offer prompt assistance and service to CELLINK’s bioprinting solution users. The collaboration will prioritize knowledge sharing, training, and technical support, ensuring that researchers in Portugal and Spain can fully harness the capabilities of CELLINK’s cutting-edge bioprinting platforms.
This partnership exemplifies CELLINK’s continued expansion efforts and its dedication to enhancing the accessibility of bioprinting technologies on a global scale. With Paralab’s well-established distribution network, researchers, scientists, and institutions in Portugal and Spain will now find it easier than ever to access CELLINK’s advanced bioprinters and bioinks.
“We are thrilled to embark on this journey with Paralab and expand our presence in Southern Europe,” stated Andrew Ridley, Head of Sales Europe, CELLINK. “Their track record of excellence, strong local presence, and commitment to customer success align with CELLINK’s core values. We are confident that this collaboration will empower researchers in Portugal and Spain to drive forward groundbreaking research in regenerative medicine, tissue engineering, and beyond.”
“We are glad we could celebrate this strategic collaboration between CELLINK and ParalabBIO which represents a commitment to advancing scientific knowledge and innovation in the field of 3D bioprinting. Together, we aim to reshape the future of 3D bioprinting in Portugal and Spain by bringing to our valued customers cutting edge technology and streamline operations with even greater value.” José Catita, Senior Manager, Paralab & ParalabBIO
For further information, please contact:
Avijit Minocha, Head of Marketing, CELLINK
Phone: +1 617 637 5372
CELLINK is enabling the future of health as part of BICO, the world’s leading bioconvergence company. When CELLINK released the first universal bioink in 2016, it democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 1000 publications and are trusted by more than 1,600 academic, pharmaceutical and industrial labs. With a comprehensive portfolio of world-class 3D bioprinters and bioinks CELLINK’s technology enables the printing of human tissues and organs, which enable faster and more accurate models for drug development, while replacing animal experiments and paving the way to save lives by reducing organ rejection and potentially solve the problem with lack of donors. 2022 CELLINK made a strategic investment to reach our business mission and continue to push the boundaries of how 3D bioprinting can contribute to the future of health. Visit www.cellink.com to learn more. BICO is listed on the Nasdaq Stockholm Main Market under BICO.